Ceribell to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) will participate in two investor conferences in early March 2026. CFO Scott Blumberg will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 at 1:00 p.m. PST / 4:00 p.m. EST.
CEO Jane Chao, Ph.D., and CFO Scott Blumberg will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 10:50 a.m. PST / 1:50 p.m. EST. Live and archived webcasts will be available in the company's Investor Relations section.
Positive
- None.
Negative
- None.
News Market Reaction – CBLL
In the Feb 19 session, CBLL gained 1.81%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings call scheduling | Neutral | -1.1% | Set date for Q4 and full-year 2025 results and webcast details. |
| Jan 05 | Regulatory designation | Positive | -2.3% | FDA Breakthrough Device Designation for LVO stroke detection solution. |
| Dec 30 | Conference participation | Neutral | +1.0% | Announcement of presentation at J.P. Morgan Healthcare Conference. |
| Dec 09 | Regulatory clearance | Positive | +5.0% | FDA 510(k) clearance for first-of-its-kind delirium monitoring solution. |
| Nov 24 | Regulatory clearance | Positive | +4.9% | FDA 510(k) clearance for Clarity algorithm across neonatal to adult patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent FDA 510(k) clearances were followed by positive moves, while a breakthrough designation and an earnings-date notice saw mild declines, indicating occasionally contrarian reactions to ostensibly positive catalysts.
Over the past few months, Ceribell has reported several notable milestones. FDA 510(k) clearances for delirium monitoring on Dec 9, 2025 and the neonatal Clarity algorithm on Nov 24, 2025 both coincided with gains near +5%. An FDA breakthrough designation for LVO stroke detection on Jan 5, 2026 and an earnings-date announcement on Feb 10, 2026 saw modest declines. Prior conference participation in Dec 2025 had a small positive reaction, providing a reference point for these new March conference appearances.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:50 a.m. Pacific Standard Time / 1:50 p.m. Eastern Standard Time.
Event: Raymond James 47th Annual Institutional Investors Conference
Date: Monday, March 2, 2026
Time: 1:00 p.m. PST / 4:00 p.m. EST
Event: TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Time: 10:50 a.m. PST / 1:50 p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
